Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS) expressing HER2. PATIENTS AND METHODS: Patients with recurren...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishikawa, Tadaaki, Hasegawa, Kosei, Matsumoto, Koji, Mori, Masahiko, Hirashima, Yasuyuki, Takehara, Kazuhiro, Ariyoshi, Kazuya, Kato, Tomoyasu, Yagishita, Shigehiro, Hamada, Akinobu, Kawasaki, Mamiko, Kawashima, Satoshi, Tomatsuri, Sawako, Nagasaka, Yukari, Yoshida, Hiroshi, Machida, Ryunosuke, Hirakawa, Akihiro, Nakamura, Kenichi, Yonemori, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414746/
https://www.ncbi.nlm.nih.gov/pubmed/36977309
http://dx.doi.org/10.1200/JCO.22.02558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414746/
https://www.ncbi.nlm.nih.gov/pubmed/36977309
http://dx.doi.org/10.1200/JCO.22.02558

Ejemplares similares